Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.
Sheppard VB, Faul LA, Luta G, Clapp JD, Yung RL, Wang JH, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher BN, Hudis C, Winer EP, Cohen HJ, Muss HB, Hurria A, Mandelblatt JS. Sheppard VB, et al. Among authors: pitcher bn. J Clin Oncol. 2014 Aug 1;32(22):2318-27. doi: 10.1200/JCO.2013.51.7367. Epub 2014 Jun 16. J Clin Oncol. 2014. PMID: 24934786 Free PMC article.
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.
Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB; Alliance for Clinical Trials in Oncology. Freedman RA, et al. Breast Cancer Res Treat. 2013 Jun;139(2):607-16. doi: 10.1007/s10549-013-2562-6. Epub 2013 May 17. Breast Cancer Res Treat. 2013. PMID: 23681403 Free PMC article.
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).
Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J. Kimmick GG, et al. Breast Cancer Res Treat. 2017 Jun;163(2):391-398. doi: 10.1007/s10549-017-4188-6. Epub 2017 Mar 10. Breast Cancer Res Treat. 2017. PMID: 28283904 Free PMC article.
Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance).
Klepin HD, Pitcher BN, Ballman KV, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG. Klepin HD, et al. Among authors: pitcher bn. J Oncol Pract. 2014 Sep;10(5):e285-92. doi: 10.1200/JOP.2014.001388. Epub 2014 Jul 29. J Oncol Pract. 2014. PMID: 25074878 Free PMC article. Clinical Trial.
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Carey LA, et al. Among authors: pitcher bn. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. J Clin Oncol. 2016. PMID: 26527775 Free PMC article. Clinical Trial.
Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance).
Mandelblatt JS, Clapp JD, Luta G, Faul LA, Tallarico MD, McClendon TD, Whitley JA, Cai L, Ahles TA, Stern RA, Jacobsen PB, Small BJ, Pitcher BN, Dura-Fernandis E, Muss HB, Hurria A, Cohen HJ, Isaacs C. Mandelblatt JS, et al. Among authors: pitcher bn. Cancer. 2016 Nov 15;122(22):3555-3563. doi: 10.1002/cncr.30208. Epub 2016 Jul 22. Cancer. 2016. PMID: 27447359 Free PMC article.
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry LN, Tolaney S, Dang CT, Krop IE, Harris LN, Berry DA, Mardis ER, Winer EP, Hudis CA, Carey LA, Perou CM. Tanioka M, et al. Among authors: pitcher bn. Clin Cancer Res. 2018 Nov 1;24(21):5292-5304. doi: 10.1158/1078-0432.CCR-17-3431. Epub 2018 Jul 23. Clin Cancer Res. 2018. PMID: 30037817 Free PMC article. Clinical Trial.
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Carey LA, Bernard PS, Nielsen TO, Perou CM, Ellis MJ, Barry WT. Liu MC, et al. Among authors: pitcher bn. NPJ Breast Cancer. 2016;2:15023-. doi: 10.1038/npjbcancer.2015.23. Epub 2016 Jan 6. NPJ Breast Cancer. 2016. PMID: 28691057 Free PMC article.
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, Ruiz-Borrego M, Munarriz B, López JA, Adamo B, Cheang MC, Li Y, Hu Z, Gulley ML, Vidal MJ, Pitcher BN, Liu MC, Citron ML, Ellis MJ, Mardis E, Vickery T, Hudis CA, Winer EP, Carey LA, Caballero R, Carrasco E, Martín M, Perou CM, Alba E. Prat A, et al. Among authors: pitcher bn. Br J Cancer. 2014 Oct 14;111(8):1532-41. doi: 10.1038/bjc.2014.444. Epub 2014 Aug 7. Br J Cancer. 2014. PMID: 25101563 Free PMC article.
33 results